

Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience

Tommaso Caravita, Agostina Siniscalchi, Andrea Tendas, Luca Cupelli, Micaela Ales, Alessio Perrotti, Pasquale Niscola, Paolo Fabritiis

▶ To cite this version:

Tommaso Caravita, Agostina Siniscalchi, Andrea Tendas, Luca Cupelli, Micaela Ales, et al.. Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience. Annals of Hematology, 2010, 90 (1), pp.115-116. 10.1007/s00277-010-0967-4. hal-00554985

HAL Id: hal-00554985 https://hal.science/hal-00554985

Submitted on 12 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. Editorial Manager(tm) for Annals of Hematology Manuscript Draft

Manuscript Number: AOHE-D-10-00151R1

Title: Safety and efficacy of a combination therapy with Revlimid, Adriamycin and Dexamethasone (RAD) in Relapsed/Refractory Multiple Myeloma (MM): a single centre experience.

Article Type: Letter to the Editor

Keywords: Multiple Myeloma, RAD regimen, salvage therapy

Corresponding Author: M.D. Agostina Siniscalchi,

Corresponding Author's Institution:

First Author: Tommaso Caravita

Order of Authors: Tommaso Caravita; Agostina Siniscalchi; Andrea Tendas; Luca Cupelli; Micaela Ales; Alessio Perrotti; Pasquale Niscola; Paolo de Fabritiis

Abstract: Despite therapeutic milestones achieved, the optimal therapy of relapsed/refractory MM remains controversial. Treatment options have increased over the last few years, especially with the availability of novel agents for routine care and within clinical trials. Lenalidomide is an oral immunemodulatory drug with significant activity in this setting and has been approved by EMEA in association with Dexamethasone for the treatment of patients with at least one prior therapy. To improve response rate and long term outcome of relapsed/refractory MM patients, new Lenalidomide combinations are investigated with promising results. Knopp et al recently reported that RAD association induces substantial and durable remission rate with an acceptable toxicity profile in pretreated MM patients.

However, in their schedule Adriamycin was given as continuous infusion over 96 hours, necessitating of patients hospitalization and sometimes a CVC insertion. A modification of Knopp RAD regimen, including Adriamycin as a bolus single dose, days 1,4, was proposed to facilitate the administration in the out patient setting.

Response to Reviewers: According to your suggestion, I have corrected the name of the first author of original RAD paper.

Thank you.

Safety and efficacy of a combination therapy with Revlimid, Adriamycin and Dexamethasone (RAD) in Relapsed/Refractory Multiple Myeloma (MM): a single centre experience

Tommaso Caravita, Agostina Siniscalchi, Andrea Tendas, Luca Cupelli, Micaela Ales, Alessio Perrotti, Pasquale Niscola and Paolo de Fabritiis

Department of Hematology S. Eugenio Hospital, "Tor Vergata" University, Rome, Italy Piazzale dell'Umanesimo, 10 00100 Rome, Italy

Corresponding Author:

- 4 Dott.ssa Agostina Siniscalchi
- 5 Department of Hematology S. Eugenio Hospital, "Tor Vergata" University
- Piazzale dell'Umanesimo, 10
- 7 00100 Rome, Italy
- Tel. +390651008983 Fax +390651002508
- e-mail: s.agostina@libero.it

Dear Editor,

Despite therapeutic milestones achieved, the optimal therapy of relapsed/refractory MM remains controversial [1]. Treatment options have increased over the last few years, especially with the availability of novel agents for routine care and within clinical trials [2]. Lenalidomide is an oral immune-modulatory drug with significant activity in this setting and has been approved by EMEA in association with Dexamethasone for the treatment of patients with at least one prior therapy [3]. To improve response rate and long term outcome of relapsed/refractory MM patients, new Lenalidomide combinations are investigated with promising results [4-6]. Knop et al recently reported that RAD association induces substantial and durable remission rate with an acceptable toxicity profile in pretreated MM patients [7].

- However, in their schedule Adriamycin was given as continuous infusion over 96 hours, necessitating of patients hospitalization and sometimes a CVC insertion. A modification of Knopp RAD regimen, including Adriamycin as a bolus single dose, days 1,4, was proposed to facilitate the administration in the out patient setting.
- Between May and December 2008, 10 patients (4 M/6 F) with relapsed/refractory MM were planned to receive six 28 days cycles RAD.
- Main pre-treatment characteristics were the following: median age 69 years (range 50-78); WHO performance status 0-3; median Hb 8.95 gr/dl (range 8.3-12.1); median B2M 4.4 mg/L (range 2.5-9.1); median bone marrow plasma cell infiltration 40% (range 5-80); median time from MM diagnosis to treatment 33 months (range 11-130). All patients had received more than two chemotherapy regimens (range 1-6). Five patients were previously treated with autologous stem cell transplantation.
- RAD schedule included: Revlimid 25 mg days 1-21, Adriamycin 40 mg/m² i.v. days 1,4,
 Dexamethasone 40 mg p.o. days 1–4. Peg-filgrastim was administrated on day 6. Aspirin 100 mg/die was given as prophylaxis for thrombosis. The International Myeloma Working Group criteria were used for definition of response [8]; toxicity was graded according to NCI-CTC criteria.
 Of the 10 pts, 2 were not evaluable for response because of early withdrawal due to progression of the disease. At the end of treatment, a clinical response was observed in 7 patients (4 VGPR and 3 CR) and disease progression in 1. The best response was observed after a median of 8 weeks of treatment (range 4-12) (Table 1).
- Myelotoxicity was the primarily and major side effect. Leukopenia and thrombocytopenia of grade were observed in 5/8 patients while of grade 4 in 1 patient, leading to dose reduction. One patient died for infectious complication (pneumonia). Other non haematological side effects were fever (1 case), fatigue (3 cases), diarrhoea (2 cases). No relevant neurological symptoms were found. After a median follow up of 54 weeks (range 8-80) all six patients have experienced a progression of disease, requiring a new salvage therapy. Median time to progression was 16 weeks (range 12-24). In conclusion, although weakened by the small number of cases and short lived duration, these data showed that this modified RAD is feasible, well tolerated and effective in refractory/relapsed MM allowing the patients management in an out patient basis.

References

1) Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, Corradini P, Corso A, Di Raimondo F, Falcone A, Ferrara F, Morabito F, Musto P, Offidani M, Petrini M, Rizzi R, Semenzato G, Tosi P, Vacca A, Cavo M, Boccadoro M, Palombo A. Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. European Journal of Haematology ISSN 0902-4441

2) Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520.

3) J.L. Harousseau (2008)New treatments in multiple myeloma: beyond optimal treatment. Annals of Oncology 19(5): v68–v70

4) Baz R, Walker E, Karam MA, et al (200&) Lenalidomide and pegylated liposomal doxorubicinbased chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 17: 1766-1771.

5) Morgan GJ, Schey SA, Wu P, et al (2007) Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol. 137:268-269.

6) Richardson PG, Jagannath S, Avigan DE, et al (2006) Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase I trial [abstract]. Blood. 108:124a. Abstract no. 405.

7) Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, Vollmuth C, Falk K, Glasmacher A, Maeder U, Einsele H and Bargou RC (2009) Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsedand refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom) Blood. 113:4137-4143.

8) Durie BGM, Harousseau JL, San Miguel J, et al (2006) International uniform response criteria for multiple myeloma. Leukemia. 20:1467-1473.

Table 1. Results

| pts | Age (years) | previous treatment lines | nr RAD | response | Time to best response weeks | TTP* (weeks) | FUP ° (weeks) |
|-----|-------------|-----------------------------|--------|----------|--------------------------------|-------------------|----------------------|
| LP | 61 | 1 | 2 | VGPR | 4 | Died in remission | 8 |
| AMM | 69 | 2 | 3 | PG | 8 | 12 | 32 |
| VF | 74 | 4 | 6 | RC | 12 | 16 | 80 |
| LC | 66 | 3 | 6 | VGPR | 8 | 12 | 52 |
| GS | 70 | 3 | 6 | RC | 8 | 24 | 60 |
| AC | 78 | 3 | 6 | VGPR | 8 | 16 | 56 |
| CA | 76 | 1 | 5 | RC | 12 | 18 | 68 |
| RM | 78 | 7 | 1 | VGPR | 12 | 14 | 40 |
| LT | 40 | 1 | 1 | PG | - | - | - |
| AL | 54 | 5 | 1 | PG | - | - | - |

* time to progression

° follow up

*Conflict of interest Click here to download Conflict of interest: Conflict of Interest Disclosure Form.doc